SCHEDULE: Point72 Discloses RxSight Stake

Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen jointly filed a Schedule 13G, reporting beneficial ownership of 6.0% of RxSight, Inc. common stock.

Summary

• This filing is a Schedule 13G, indicating a significant beneficial ownership of RxSight, Inc. common stock by Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen.
• The reporting persons collectively beneficially own 2,487,468 shares of common stock, representing 6.0% of the class.
• The shares are held by Point72 Associates, LLC, an investment fund managed by Point72 Asset Management.
• Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management, and Steven A. Cohen controls both entities.
• The filing confirms a joint filing agreement was in place, with each party responsible for the accuracy of their own information but not that of others unless known.
• The date of the event requiring the filing was August 12, 2026, and the statement was signed on August 19, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative update regarding beneficial ownership thresholds rather than a reflection of new company performance or strategy.

Positives

• Significant institutional ownership by a well-known investment firm (Point72) can signal confidence in the company's long-term prospects.
• The filing clearly delineates the reporting structure and beneficial ownership, providing transparency to the market.

Negatives

• The filing does not provide any new financial performance data or strategic updates for RxSight, Inc.
• The information is purely related to ownership and does not offer insights into the company's operational health or future plans.

Risks

• While not explicitly stated as a risk in this filing, significant ownership by a single entity can sometimes lead to concentrated decision-making or potential for rapid share sales if the entity's strategy changes.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding RxSight, Inc.'s future performance or strategy.

Management Comments

• Each of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934 (the 'Act').
• The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors crossing certain ownership thresholds. This filing indicates Point72's increased interest or established position in RxSight, Inc., a company operating in the medical technology sector, specifically related to ophthalmic solutions.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant institutional ownership by Point72 may influence investor sentiment and trading activity.
• Management of RxSight, Inc.: The filing confirms a substantial stake held by a major investment firm, which could imply potential engagement on strategic matters.

Next Steps

• The reporting persons will continue to monitor their beneficial ownership of RxSight, Inc. common stock.
• Subsequent amendments to this Schedule 13G will be filed as required by SEC regulations.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Point72 Asset Management, Point72 Capital Advisors, Steven A. Cohen, RxSight, Inc., Institutional Investor, Investment Management